In particular, it provided evidence of preferential MC trajectories in diseases such as COPD/PF, dominated by late alarmin/pro‐fibrotic responses, and IFNγ/IL‐33 inflammation in COVID‐19, which further corroborate and expand our knowledge of the pathogenic mechanisms involving MCs in disease [47, 93]. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.